胰腺癌mRNA疫苗的研究进展

被引:0
|
作者
黄鸿才 [1 ]
余华 [2 ]
机构
[1] 成都中医药大学医学与生命科学学院
[2] 成都中医药大学附属医院普外科
关键词
胰腺癌; 精准治疗; 癌症疫苗; mRNA疫苗; 肿瘤抗原; 免疫亚型;
D O I
暂无
中图分类号
R735.9 [胰腺肿瘤];
学科分类号
摘要
目的 探讨mRNA疫苗作为胰腺癌个体化精准治疗新策略的可行性。方法 回顾性收集国内外近年来关于胰腺癌中疫苗研究的相关文献并进行综述。结果 胰腺癌因其肿瘤间和肿瘤内的异质性,导致基于细胞、外泌体、蛋白质、肽或DNA的常规胰腺癌疫苗的疗效未达预期,而mRNA疫苗因其精确靶向、低毒性、能够诱导持久免疫记忆等优势,被视为胰腺癌治疗有前景的替代疗法。通过在肿瘤抗原识别、免疫亚型区分和mRNA疫苗构建上的突破,胰腺癌mRNA疫苗的研制策略已进一步推动个体化精准医疗的发展。现有的mRNA疫苗通常需与其他免疫治疗方法结合以提高疗效,而且预防性疫苗的开发仍在探索阶段。结论 mRNA作为一种创新且有前景的载体,为胰腺癌疫苗的开发提供了新的希望。然而由于常规疫苗的局限性以及胰腺癌本身的肿瘤异质性特点,使胰腺癌疫苗研究面临不小挑战,而mRNA疫苗的优势使它用于治疗胰腺癌成为可能。面对胰腺癌复杂特征的挑战,需要更多的研究来支持实现mRNA疫苗在临床治疗中的转化应用。
引用
收藏
页码:244 / 251
页数:8
相关论文
共 67 条
  • [11] Recent Advances in Site-Specific Lipid Nanoparticles for mRNA Delivery
    Xu, Xiao
    Xia, Tian
    [J]. ACS NANOSCIENCE AU, 2023, 3 (03): : 192 - 203
  • [12] Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer
    Xiao, Li
    Erb, Ulrike
    Zhao, Kun
    Hackert, Thilo
    Zoeller, Margot
    [J]. ONCOIMMUNOLOGY, 2017, 6 (06):
  • [13] Tools for translation: non-viral materials for therapeutic mRNA delivery
    Hajj, Khalid A.
    Whitehead, Kathryn A.
    [J]. NATURE REVIEWS MATERIALS, 2017, 2 (10):
  • [14] Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
    Sahin, Ugur
    Derhovanessian, Evelyna
    Miller, Matthias
    Kloke, Bjoern-Philipp
    Simon, Petra
    Loewer, Martin
    Bukur, Valesca
    Tadmor, Arbel D.
    Luxemburger, Ulrich
    Schroers, Barbara
    Omokoko, Tana
    Vormehr, Mathias
    Albrecht, Christian
    Paruzynski, Anna
    Kuhn, Andreas N.
    Buck, Janina
    Heesch, Sandra
    Katharina, H.
    Mueller, Felicitas
    Ortseifer, Inga
    Vogler, Isabel
    Godehardt, Eva
    Attig, Sebastian
    Rae, Richard
    Breitkreuz, Andrea
    Tolliver, Claudia
    Suchan, Martin
    Martic, Goran
    Hohberger, Alexander
    Sorn, Patrick
    Diekmann, Jan
    Ciesla, Janko
    Waksmann, Olga
    Burck, Alexandra-Kemmer
    Witt, Meike
    Zillgen, Martina
    Rothermel, Andree
    Kasemann, Barbara
    Langer, David
    Bolte, Stefanie
    Diken, Mustafa
    Kreiter, Sebastian
    Nemecek, Romina
    Gebhardt, Christoffer
    Grabbe, Stephan
    Holler, Christoph
    Utikal, Jochen
    Huber, Christoph
    Loquai, Carmen
    Tuereci, Oezlem
    [J]. NATURE, 2017, 547 (7662) : 222 - +
  • [15] Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer
    Makohon-Moore, Alvin P.
    Zhang, Ming
    Reiter, Johannes G.
    Bozic, Ivana
    Allen, Benjamin
    Kundu, Deepanjan
    Chatterjee, Krishnendu
    Wong, Fay
    Jiao, Yuchen
    Kohutek, Zachary A.
    Hong, Jungeui
    Attiyeh, Marc
    Javier, Breanna
    Wood, Laura D.
    Hruban, Ralph H.
    Nowak, Martin A.
    Papadopoulos, Nickolas
    Kinzler, Kenneth W.
    Vogelstein, Bert
    Iacobuzio-Donahue, Christine A.
    [J]. NATURE GENETICS, 2017, 49 (03) : 358 - 366
  • [16] DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.[J].TiptiriKourpeti Angeliki;Spyridopoulou Katerina;Pappa Aglaia;Chlichlia Katerina.Pharmacology & therapeutics.2016,
  • [17] Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
    Moffitt, Richard A.
    Marayati, Raoud
    Flate, Elizabeth L.
    Volmar, Keith E.
    Loeza, S. Gabriela Herrera
    Hoadley, Katherine A.
    Rashid, Naim U.
    Williams, Lindsay A.
    Eaton, Samuel C.
    Chung, Alexander H.
    Smyla, Jadwiga K.
    Anderson, Judy M.
    Kim, Hong Jin
    Bentrem, David J.
    Talamonti, Mark S.
    Iacobuzio-Donahue, Christine A.
    Hollingsworth, Michael A.
    Yeh, Jen Jen
    [J]. NATURE GENETICS, 2015, 47 (10) : 1168 - +
  • [18] Pancreatic cancer: Role of the immune system in cancer progression and vaccine-based immunotherapy
    Amedei, Amedeo
    Niccolai, Elena
    Prisco, Domenico
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (11) : 3354 - 3368
  • [19] Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
    Middleton, Gary
    Silcocks, Paul
    Cox, Trevor
    Valle, Juan
    Wadsley, Jonathan
    Propper, David
    Coxon, Fareeda
    Ross, Paul
    Madhusudan, Srinivasan
    Roques, Tom
    Cunningham, David
    Falk, Stephen
    Wadd, Nick
    Harrison, Mark
    Corrie, Pippa
    Iveson, Tim
    Robinson, Angus
    McAdam, Karen
    Eatock, Martin
    Evans, Jeff
    Archer, Caroline
    Hickish, Tamas
    Garcia-Alonso, Angel
    Nicolson, Marianne
    Steward, William
    Anthoney, Alan
    Greenhalf, William
    Shaw, Victoria
    Costello, Eithne
    Naisbitt, Dean
    Rawcliffe, Charlotte
    Nanson, Gemma
    Neoptolemos, John
    [J]. LANCET ONCOLOGY, 2014, 15 (08): : 829 - 840
  • [20] Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer The CONKO-001 Randomized Trial
    Oettle, Helmut
    Neuhaus, Peter
    Hochhaus, Andreas
    Hartmann, Joerg Thomas
    Gellert, Klaus
    Ridwelski, Karsten
    Niedergethmann, Marco
    Zuelke, Carl
    Fahlke, Joerg
    Arning, Michael B.
    Sinn, Marianne
    Hinke, Axel
    Riess, Hanno
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (14): : 1473 - 1481